Vol.

No.

April 19, 2024Apr 19, 2024

DOWNLOAD THE PDF

“This is our time, and the time is now”—Chapman tells us about Jefferson’s final push for Comprehensive designation

Cover Story

Conversation with The Cancer Letter

“This is our time, and the time is now”—Chapman tells us about Jefferson’s final push for Comprehensive designation

By Paul Goldberg

Sidney Kimmel Cancer Center at Jefferson Health can add the word “Comprehensive” to its name, becoming the 57th institution to earn this top-level designation from NCI.

Guest Editorial

Leading a Comprehensive Cancer Center—one job or two?

By George J. Weiner

Guest Editorial

Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusion
Minority Cancer Awareness Week

By Kimlin Tam Ashing, Nadine J. Barrett, Kim F. Rhoads, Folakemi T. Odedina, Hayley S. Thompson and Camille C. R. Ragin

Cancer History Project Free

Surviving lung cancer focused Morhaf Al Achkar’s career on addressing health disparities

By McKenzie Prillaman

Free In the Archives

Tobacco in the tabloids: How the Weekly World News covered smoking for laughs—and the National Enquirer wouldn’t cover it at all

In Brief

Andrew Smith named chair of St. Jude Diagnostic Imaging Department

NCI renews MUSC Hollings support grant with “outstanding” rating

Matsumoto, Wald, Woodard, Everett named to ACR leadership positions

Jorge Cortes named editor-in-chief of Blood Global Hematology

William Donovan receives ACR Thorwarth Award

McGowan receives RLI Leadership Award

NCCN awards go to Green, Kumar, Black, and the COVID-19 Vaccination Advisory Committee

Burke, Muir, Rauschecker, Smithy, Vega receive NCCN Foundation Young Investigator Awards

Fox Chase opens newly-expanded Buckingham site

Chuckstrong Tailgate Gala raises $1.5M for IU cancer research

Funding Opportunities

FDA offers funding for meetings on medical policy activities

DOD Kidney Cancer Research Program funding opportunities for FY24

Clinical Roundup

PRECEDE study points to screening method for pancreatic cancer

CAP publishes guideline for PD-L1 testing for lung cancer

Urine test improves non-invasive detection of prostate cancer

Columvi improves OS in R/R DLBCL in phase III trial

Clinical tool predicts immunotherapy response in uveal melanoma patients

Subgroup analysis focuses on P-BCMA-ALLO1 allogeneic CAR T in multiple myeloma

Drugs & Targets

FDA approves Alecensa for ALK-positive early-stage lung cancer

FDA approves Lumisight to assist breast cancer detection

MD Anderson and CureVac collaborate to develop mRNA cancer vaccines

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues